The United States of America, As Represented by the Secretary, Department of Health and Human Services

Pontificia Universidad Catòlica De Chile

Pontifica Universidad Catoclica De Chile

Alejandra Alvarez

Juan Jose Marugan

Noel Terrence Southall

Xin Hu

Marc Ferrer

Rommy M Von Bernhardi

Silvana Zanlungo

Daniel C Talley

Christopher R Dextras

Andres E Dulcey

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as 'c-Abl'). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Growing community of inventors

Santiago, Chile

Alejandra Alvarez